Topic: Lymphoma Treatments
Eisai and Celgene veteran Michael Amoroso will take on the challenge of making Gilead's entrance into CAR-T cancer treatments a success.
Can Roche's Gazyva edge Rituxan even with biosims looming? At least one analyst thinks it may be the only second-gen blood cancer med with a chance to stand out.
AbbVie and its development partners have big plans for the upcoming American Society of Hematology (ASH) meeting that starts Dec. 3.
Celgene’s best-selling drug Revlimid fell short in a lymphoma trial, putting its hopes for a $1 billion revenue boost in danger.
Roche’s Gazyva fell short in a late-stage lymphoma trial, jeopardizing the company’s expansion plans for the Rituxan follow-up.